
Mitral valve transcatheter edge‐to‐edge repair (M‐TEER) is a guideline‐recommended treatment option for patients with secondary mitral regurgitation (SMR). The purpose of this analysis is to report contemporary real‐world outcomes in SMR patients treated with 3rd generation MitraClip systems. Under real‐world conditions, optimal sustained MR reduction to MR≤1+ was achieved in a high percentage of patients with 3rd generation MitraClip, which translated into symptomatic improvement and low event rates.
Like
Save
Share